These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 3915152)
1. [How do we handle cytostatics?]. Mihăescu T Rev Med Chir Soc Med Nat Iasi; 1985; 89(4):748-50. PubMed ID: 3915152 [No Abstract] [Full Text] [Related]
2. [Nurses' exposure to cytostatics in the handling of cytostatics. Theoretical lesson and clinical study]. Johansson I; Bergenfelz A; Wadbo M SHSTF; 1981 Aug; (7):1-29. PubMed ID: 6914812 [No Abstract] [Full Text] [Related]
3. [Cytostatics in the hospital. All that it is important to know]. Armentia Agüero L; Mur Mur AM; Ramos Díaz F; Sánches Fresneda MN; Sevilla Azzati E Rev Enferm; 1991 Jun; 14(154):75-80. PubMed ID: 1862294 [No Abstract] [Full Text] [Related]
4. Do carcinogens in the hospital pose a risk to health-care workers? Oncology (Williston Park); 1994 Mar; 8(3):74. PubMed ID: 8018484 [No Abstract] [Full Text] [Related]
5. Quantification of urinary mutagens in nurses during potential antineoplastic agent exposure. A pilot study with concurrent environmental and dietary control. Caudell KA; Vredevoe DL; Dietrich MF; Caudell TP; Hoban MJ; Block JB Cancer Nurs; 1988 Feb; 11(1):41-50. PubMed ID: 3359427 [No Abstract] [Full Text] [Related]
6. [The possible mutagenic effects of cytostatics on nurses in an oncology department]. Bastholt L Ugeskr Laeger; 1984 Aug; 146(35):2610-3. PubMed ID: 6515872 [No Abstract] [Full Text] [Related]
7. Risk and reason. Risk assessment in relation to environmental mutagens and carcinogens. Proceedings of a satellite symposium to the Fourth International Conference on Environmental Mutagens. Oslo, Norway, June 21-22, 1985. Prog Clin Biol Res; 1986; 208():1-189. PubMed ID: 3960880 [No Abstract] [Full Text] [Related]
11. Re-evaluation of urine mutagenicity of pharmacy personnel exposed to antineoplastic agents. Connor TH; Theiss JC; Anderson RW; Puckett WH; Matney TS Am J Hosp Pharm; 1986 May; 43(5):1236-9. PubMed ID: 3521267 [No Abstract] [Full Text] [Related]
12. Cancer risks of medical treatment. Part I: Monitoring for drug safety and efficacy. Schottenfeld D Clin Bull; 1980; 10(4):150-7. PubMed ID: 7011593 [No Abstract] [Full Text] [Related]
13. [Safety for the handling of cytostatic substances. Protective measures are useful]. Schmid B Krankenpfl Soins Infirm; 1985 Jul; 78(7):39-41, 66-8. PubMed ID: 3850203 [No Abstract] [Full Text] [Related]
14. [Health effects of occupational exposure to cytostatics in medicinal personnel in the light of compulsory prophylactics: a cross-sectional study]. Walusiak J; Wagrowska-Koski E; Pałczyński C Med Pr; 2003; 54(3):229-36. PubMed ID: 14669575 [TBL] [Abstract][Full Text] [Related]
15. [Precautionary measures during preparation and infusion of cytostatics]. Gundersen S Tidsskr Nor Laegeforen; 1976 Sep; 96(26):1388. PubMed ID: 135376 [No Abstract] [Full Text] [Related]
16. [Cytogenetic indicators of genotoxicity in subjects occupationally exposed to antineoplastic drugs]. Forni A; Bonatti S; Merler E Med Lav; 1996; 87(3):222-9. PubMed ID: 8965735 [TBL] [Abstract][Full Text] [Related]
17. Hazards of cancer chemotherapy. Lancet; 1982 Dec; 2(8311):1317-8. PubMed ID: 6128606 [No Abstract] [Full Text] [Related]
18. [Occupational risk in the handling of chemotherapeutic agents]. Wagener DJ Ned Tijdschr Geneeskd; 1986 Dec; 130(51):2292-4. PubMed ID: 3821947 [No Abstract] [Full Text] [Related]
19. Perspectives on occupational exposure to antineoplastic drugs. Fishbein L Arch Geschwulstforsch; 1987; 57(3):219-48. PubMed ID: 3304187 [TBL] [Abstract][Full Text] [Related]
20. [Are the cytostatic drugs and their metabolites, excreted by patients during chemotherapy, hazardous for the family environment?]. Piekarczyk A; Grzesiuk E; Zimak J; Taljanski W Med Wieku Rozwoj; 2001; 5(3 Suppl 1):63-70. PubMed ID: 12004153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]